Jacques Corbeil at the heart of a collaborative project of more than $ 1.2 million for the optimization of vaccine production

The CQDM biopharmaceutical research consortium and Medicago R&D are proud to announce today the funding of a research project that will allow the Quebec City-based company to strengthen its leadership in the biopharmaceutical industry in Canada and increase the competitiveness of its vaccine production. Through CQDM, the Quebec Ministry of Economy and Innovation is providing a $ 500,000 grant for this three-year initiative.

“The COVID-19 health crisis reminds us of the importance of producing vaccines to ensure the protection and health of the population. More than ever, the government of Quebec considers it essential to support this research project, which will allow Medicago, a major player in the biopharmaceutical industry, to increase its productivity thanks to artificial intelligence. At the same time, we will strengthen Quebec’s position as one of the most important vaccine manufacturing centers in the world,” said Pierre Fitzgibbon, Minister of Economy and Innovation.

The project is led by the team of Professor Jacques Corbeil, a researcher in the Department of Molecular Medicine at the CHU de Québec-Université Laval as well as a member of IID, and is carried out in close collaboration with Medicago R&D. Professor Corbeil holds a Canada Research Chair in Medical Genomics, and is internationally recognized for his in-depth expertise in medicine and machine learning approaches.

 “It is important to note that this project arises from the common goal we all share of improving vaccine production in order to protect the health of Canadians. This strong support is particularly timely in our battle against emerging diseases that we must face today, such as COVID-19,” said Professor Corbeil.

Read the full press release on the CQDM website

Read a summary of this article in ULaval Nouvelles

Let’s keep in touch!

Would you like to be informed about IID news and activities? Subscribe now to our monthly newsletter.